Analysts expect scPharmaceuticals to post earnings of ($0.39) per share and revenue of $12.08 million for the quarter. scPharmaceuticals Price Performance Shares of NASDAQ:SCPH opened at $2.93 on ...

Rhumbline Advisers’ holdings in scPharmaceuticals were worth $151,000 at the end of the most recent quarter. Several other hedge funds have also made changes to their positions in SCPH.

The Food and Drug Administration (FDA) has expanded the approval of Furoscix® (furosemide injection) to include the treatment of edema in patients with ...

Last week’s significant research news included positive new Phase III data on Tezspire in nasal polyps from Amgen and ...

According to scPharmaceuticals, no additional clinical trials were needed to expand the indication to include CKD patients as a bridging approach was implemented using furosemide injection ...

Actor Gene Hackman died of heart disease with complications from Alzheimer's disease, forensic experts concluded, while his ...

In a report released today, Stacy Ku from TD Cowen maintained a Buy rating on Astria Therapeutics (ATXS – Research Report), with a price target ...

(Politico) The FDA expanded the approval of furosemide (Furoscix) to include treatment of edema in adults with chronic kidney disease, drugmaker scPharmaceuticals announced. Pope Francis ...

Lineage Cell (LCTX) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.03 per share a year ago. These figures are ...

After hours: March 7 at 7:57:37 p.m. EST Loading Chart for SCPH ...